Stifel Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino maintains a 'Buy' rating on Syndax Pharmaceuticals (NASDAQ:SNDX), but has lowered the price target from $38 to $36.

October 26, 2023 | 7:39 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Stifel maintains a 'Buy' rating on Syndax Pharmaceuticals but lowers the price target from $38 to $36. This could potentially impact the stock's performance.
While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the expected future performance of the stock. However, the impact on the stock's short-term performance is uncertain as it depends on how investors interpret and react to this news.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100